<DOC>
	<DOCNO>NCT00001649</DOCNO>
	<brief_summary>This study evaluate effectiveness drug valaciclovir prevent transmission genital herpes infect uninfected sexual partner . Genital herpes cause herpes simplex virus 2 ( HSV-2 ) , , infrequently herpes simplex virus 1 ( HSV-1 ) . Valaciclovir prevent herpes virus multiplying may also reduce transmission partner . Couples 18 year age old one partner infect HSV-2 ( source partner ) ( susceptible partner ) , may eligible study . Candidates screen blood test routine laboratory study verify presence absence HSV-2 HSV-1 infection . Participants give medical history , undergo physical examination , include genital examination , receive counsel safe sex practice recognize sign symptom possible first episode genital herpes . Source partner also counsel transmission genital herpes , susceptible partner interview sexual history practice . The source partner randomly assign take either 500-mg tablet valaciclovir placebo ( pill active ingredient ) daily 8 month . All participant give diary card complete month-the source partner record drug side effect susceptible partner record sign symptom possible HSV infection . Participants see clinic month 8 month . At visit , source partner 1 ) return unused study medication complete diary card ; 2 ) discus adverse drug side effect experience last month ; 3 ) review medication study drug take last month ; 4 ) undergo counsel safe sex practice , transmission genital herpes , recognize sign symptom first episode genital herpes ; 5 ) review symptom recurrence genital herpes experience last month . During final visit , also provide blood sample routine test possible use future study . Susceptible partner 1 ) blood sample drawn HSV testing ; 2 ) undergo safer sex counseling ; 3 ) review symptom experience last month ; 4 ) interview sexual exposure practice ; 5 ) return complete diary card . Source partner recurrence genital HSV study ask lesion culture offer open-label valaciclovir treatment . Susceptible partner contract genital herpes source partner study genital examination verify fist episode genital herpes receive 10 day open-label treatment valaciclovir . Cultures take mouth genitals , current medical condition review , blood sample draw treatment day 1 10 , treatment side effect review day 5 10 . At end study , infected partner offer 12-month course valaciclovir , one 500-mg tablet daily . Participants follow clinic every 3 month provide blood sample , return unused study medication diary card , discuss drug side effect , review medication take besides study drug , review symptom recurrence genital herpes . All participant ask complete questionnaire gathering information people genital herpes people risk infection .</brief_summary>
	<brief_title>Valaciclovir Prevent Transmission Herpes Simplex Virus</brief_title>
	<detailed_description>This randomize , multicenter , double-blind , placebo-controlled Phase III study evaluate effect valaciclovir prevent transmission herpes simplex virus ( HSV ) heterosexual couple discordant presence herpes simplex type 2 virus ( HSV-2 ) antibody . The seropositive source partner randomize receive valaciclovir 500 mg daily placebo 8 month , susceptible seronegative partner monitor clinical subclinical ( serological ) acquisition HSV . Couples must 18 year age old , general good health , monogamous relationship . Source partner must seropositive HSV-2 , history genital herpes recurrence , experience less 10 recurrence per year , suppressive therapy upon entry study . Susceptible partner must HSV-2 seronegative . The couple stratify base gender HSV status susceptible partner 2:2:1:1 ratio [ HSV-1 negative female : HSV-1 positive female : HSV-1 negative male : HSV-1 positive male ] . They randomize either valaciclovir 500 mg daily placebo ( 1:1 randomization ) within stratum . The primary endpoint proportion couple clinical evidence first episode genital HSV susceptible partner laboratory confirmation . Secondary endpoint time clinical symptom genital HSV susceptible partner , time seroconversion susceptible partner , time first recurrence HSV source partner . A total 1500 couple randomize study . Assuming 3 % incidence placebo arm reduction 75 % risk show clinical evidence genital HSV , study least 80 % power two-tailed test 5 % level significance . The safety tolerance valaciclovir assess laboratory evaluation occurrence nature adverse event . The study conduct approximately 35 outpatient center United States , Canada Europe , therefore expect center enroll 40 60 couple .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>INCLUSION CRITERIA SOURCE PARTNER 18 year age old . General good health determine current medical status laboratory test . Active heterosexual relationship susceptible partner . Presence HSV2 serum antibody determine Western blot analysis . History symptomatic recurrent genital herpes . Off HSV suppressive therapy upon enter study . In opinion investigator , able comply protocol requirement . In investigator 's opinion , subject must candidate receive suppressive therapy management disease . Written informed consent . EXCLUSION CRITERIA SOURCE PARTNER : Patients know suspect immunocompromised ( e.g. , patient receive immunosuppressive therapy , patient malignancy seropositive HIV ) . Subjects history 10 HSV recurrence per year . Impaired renal function define serum creatinine great 1.5 mg/dL estimate creatinine clearance le 30 ml/min . Impaired hepatic function define alanine transaminase ( ALT ) level great 3 time normal upper limit . Known resistance aciclovir , famciclovir , ganciclovir . Known hypersensitivity aciclovir , valaciclovir , famciclovir , ganciclovir . Malabsorption syndrome gastrointestinal dysfunction might impair drug dynamic . Subjects know lactose intolerant . Women contemplate pregnancy within duration study drug dose study . Women child bear potential use effective method contraception . Positive pregnancy test ( pregnant female nurse mother ) . INCLUSION CRITERIA SUSCEPTIBLE PARTNER 18 year age old . General good health determine current medical status . Active monogamous , heterosexual relationship source partner . Absence HSV2 serum antibody determine Western blot analysis . In investigator 's opinion , able comply protocol requirement . Written informed consent . EXCLUSION CRITERIA SUSCEPTIBLE PARTNER : Subjects know suspect immunocompromised ( e.g. , patient receive immunosuppressive therapy , patient malignancy seropositive HIV ) . Subjects receive active HSV vaccine ( subject know receive placebo clinical trial eligible ) . Presence symptomatic genital herpes . Subjects sexual relation anyone source partner . Women contemplate pregnancy within time period study . Women childbearing potential use effective method contraception . Positive pregnancy test ( pregnant female nurse mother ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Sexual Transmitted Disease</keyword>
	<keyword>Phase III</keyword>
	<keyword>HSV</keyword>
	<keyword>Valtrex</keyword>
	<keyword>Valaciclovir</keyword>
	<keyword>HS2A/B3009</keyword>
	<keyword>Herpes Simplex Virus Transmission</keyword>
	<keyword>Heterosexual Couples</keyword>
</DOC>